RxDoctor Payments Data

Ryan Wong, MD

Nephrology · Tucson, AZNPI 1174910053

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 33.4% of the total. That places this record below the midpoint for nephrology clinicians in AZ, where the typical reported total is $2,217.

$442in general payments, 2019–2025

Across 7 payments — averaging $63.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$148
  • Akebia Therapeutics Inc$127
  • Sanofi$77
  • Genentech, Inc.$26
  • Genentech USA, Inc.$22
  • Coherus Oncology, Inc.$22
  • plus $20 from 1 others
$7,350in research payments, 2019–2025

Across 3 payments — averaging $2450.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$4K
  • Novartis$3K

What the payments were for

  • Food & beverage$442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$442 in reported general payments places this provider in the 20th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$61,695
Medicare patients
220
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GalafoldMigalastat Hcl16$496,769
OzempicSemaglutide59$71,376
RybelsusSemaglutide18$42,396
FarxigaDapagliflozin Propanediol35$41,238
JardianceEmpagliflozin21$33,161
EliquisApixaban18$21,329
KerendiaFinerenone15$14,044
Sevelamer Carbonate19$6,266
Potassium Citrate ErPotassium Citrate34$2,613
Midodrine Hcl11$2,282
Torsemide47$2,014
Cinacalcet Hcl18$1,910
Calcium Acetate11$1,704
Bumetanide15$1,123
Telmisartan41$1,048

Paid to pharmacies, not to this prescriber.

Other nephrology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →